2 study, indicated for the treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). The data showed that at the cutoff date, four objective responses were noted with signs of hematologic recovery in 15 patients (8 MDS and 7 AML). All tested doses – 200mg, 300mg, 400mg and 500mg twice daily - caused bone marrow blast reductions.
https://www.tipranks.com/news/article/impressive-data-for-cancer-drug-gives-curis-stock-more-room-to-run
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Jul 2021 to Aug 2021 Click Here for more Curis Charts.
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Aug 2020 to Aug 2021 Click Here for more Curis Charts.